What are the main functions and effects of tofacitinib? What diseases does it have significant effect on treating?

Tofacitinib is an oral Janus kinase (JAK) inhibitor. It mainly interferes with cell signaling by inhibiting the JAK pathway, thereby reducing the immune system's attack on the body's own tissues, and has significant anti-inflammatory effects. Its mechanism of action can effectively regulate the immune response, especially inhibiting the inflammatory process associated with autoimmune diseases. The anti-inflammatory effects of tofacitinib make it an important drug in the treatment of many autoimmune diseases.

Tofacitinib is approved to treat rheumatoid arthritis, a common chronic inflammatory disease that causes joint pain, swelling and deformation. By inhibiting signaling molecules in the immune system that trigger inflammation, tofacitinib can effectively reduce joint inflammation and improve patients' functional activity levels. Its efficacy is often particularly prominent in situations where other traditional treatments are ineffective or produce major side effects.

In addition to rheumatoid arthritis, tofacitinib is also approved to treat ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease in which patients typically present with symptoms such as abdominal pain, diarrhea, and bloody stools. By inhibiting cytokines related to intestinal inflammation, tofacitinib can help reduce symptoms, alleviate the condition, and enable some patients to achieve clinical remission. The drug offers a new treatment option, especially for patients for whom traditional treatments have not responded.

In addition, tofacitinib has also shown good results in the treatment of ankylosing spondylitis. Ankylosing spondylitis is a disease characterized by inflammation of the spine and joints, and patients may experience severe pain and loss of movement. Tofacitinib helps alleviate symptoms and improve patients' quality of life by suppressing immune responses. Tofacitinib offers an effective treatment alternative for patients who have had a poor response to biologics.

Reference materials:https://www.xeljanz.com/